Stereotaxis Announces CFO Transition
September 16 2019 - 05:00PM
Stereotaxis (NYSE American: STXS), the global leader in innovative
robotic technologies for the treatment of cardiac arrhythmias,
today announced that Kimberly Peery has been appointed Stereotaxis
Chief Financial Officer, effective October 1, 2019. Martin Stammer,
who has served as Chief Financial Officer since 2013, has accepted
a position as the CFO of a large professional services firm
headquartered in the St. Louis area and will resign from the
Company, effective September 30, 2019.
“I have really enjoyed my time at Stereotaxis
and firmly believe in the future of the Company,” said Martin
Stammer. “I have the utmost confidence in Kim and her team and look
forward to seeing them achieve many additional milestones.”
Kimberly Peery joined Stereotaxis in 2003 and
currently serves as Vice President of Finance. Prior to
Stereotaxis, she served as a controller at various private
companies. Ms. Peery is a Certified Public Accountant and earned a
Bachelor of Science in Accounting and Master of Science in
Accounting and Computer Science from Southern Illinois University,
Edwardsville. She commented, “I appreciate the confidence placed in
me by the Stereotaxis Board of Directors and look forward to
becoming CFO in this exciting period for Stereotaxis.”
David Fischel, Chairman and CEO of Stereotaxis,
commented, “I appreciate Marty’s contributions to Stereotaxis over
many years and wish him well in his future endeavors. He leaves us
in a strong position following our recently completed financing and
uplisting to the NYSE American. I am excited to work with Kim and
congratulate her on her new leadership role.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis’ robotic technology has
received various regulatory clearances in the United States,
European Union, Japan, Canada, China, and elsewhere. The
Stereotaxis Genesis RMN System is CE marked and will become
available in other global geographies subject to regulatory
approvals. Stereotaxis Imaging Model S is CE marked and FDA
cleared. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to raise additional capital on a
timely basis and on terms that are acceptable, its ability to
continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend,
repay or refinance indebtedness, or to obtain additional financing,
in either case on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Martin C. StammerChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2023 to Mar 2024